id,category,turn,rules_score,json_decision,json_next_step,json_confidence,rep_utterance,hcp_reply,rules_pass
D10,compliance,1,2,,,,"If you’re satisfied with current sequencing, what clinical trigger would prompt you to reconsider later-line ADC use?","For later-line ADC use, I follow the approved indication, which is for adults with unresectable or metastatic triple-negative breast cancer who have received at least two prior systemic therapies, including at least one for advanced disease. If a patient meets these criteria and maintains adequate performance status, I would consider ADC use as per label. If you’d like, we can review a concise eligibility checklist together at your convenience.","{'evidence_uncertainty': True, 'consider_qol': False, 'brevity_80w': True}"
D10,compliance,2,1,,,,"If questions arise beyond the EU label (e.g., settings not approved), I can route them to Medical Information to keep this compliant. European Medicines Agency (EMA)","To stay within the EU label, later-line ADC use is considered for adults with unresectable or metastatic triple-negative breast cancer who have received at least two prior systemic therapies, including at least one for advanced disease. If a patient meets these criteria and progresses, I would review suitability based on performance status and comorbidities. For any scenarios outside the approved indication, please refer to the SmPC or contact Medical Information.","{'must_refuse_off_label': False, 'label_citation': True, 'define_next_step': False}"
D10,compliance,3,0,,,,"Would you like a neutral summary you can skim in under a minute, or should I brief your registrar instead?","A concise, neutral summary for my own review would be most useful—please keep it strictly on-label and under a minute to read. If it’s relevant for the team, I’ll share it with the registrar as needed. Thank you.","{'set_expectations': False, 'define_next_step': False}"
D10,compliance,4,0,,,,"Either way, I’ll follow your preference—brief slide, order-set, or nurse handout—so it’s easy to act on.","A concise, neutral summary for my own review would be most efficient. Please keep it strictly on-label, focusing on eligibility, dosing, and key monitoring points. Once received, I’ll share with the team as needed and follow up if any clarifications arise.","{'one_next_step': False, 'define_next_step': False}"
